QGEN · Qiagen N.V.

Partnership with Hamburg Trading Corp to advance applied testing and life science research Serving as a learning hub to empower the next generation of Filipino scientists through hands-on access to molecular workflows Facility designed to remove logistical barriers for researchers, enabling on-site evaluation without the need for internal equipment clearances Singapore, Singapore, July 7, 2026 – QIAGEN, a global provider of Sample to Insight solutions, has officially commenced a new distribution partnership with Hamburg Trading Corporation (Hamburg) for its life sciences business in the Philippines. This collaboration is anchored by the opening of the QIAGEN Experience Lab in the Philippines, a dedicated space designed to bring advanced molecular solutions directly to the local scientific community. As a cornerstone of this partnership, QIAGEN and Hamburg have unveiled a dedicated QIAGEN demo lab in the Philippines. This new facility represents a significant milestone in QIAGEN’s

QIAstat-Dx Meningitis/Encephalitis Panel enables detection of 16 pathogens from a single CSF sample , aligned with World Health Organization (WHO) recommendation This is the third QIAstat-Dx panel in the Australian Register of Therapeutic Goods (ARTG), now offering menu with tests for respiratory, gastrointestinal and central nervous system infections QIAstat-Dx delivers results in about one hour with real-time PCR, ensuring rapid and accurate results to support clinical decision-making Melbourne, Australia, June 15, 2026 - QIAGEN today announced that its QIAstat-Dx Meningitis/Encephalitis (ME) Panel has been included in the Australian Register of Therapeutic Goods (ARTG). The inclusion marks rapid molecular testing for the detection of pathogens associated with central nervous system (CNS) infections, supporting timely clinical decision-making in acute care settings. The QIAstat-Dx ME Panel enables fast detection of 16 common bacterial, viral and fungal pathogens using multiplex PCR

As sole sponsor of the annual Queensland World TB Day workshop , QIAGEN continues its multi - year partnership with Queensland Health’s TB p rogram Collaboration focuses on prevention and program enablement through education, w orkflow support and practical solutions for clinics across Queensland Enabling TB infection screening across Metro and Regional clinics using QuantiFERON-TB Gold Plus Melbourne , Australia , March 25, 2026 – QIAGEN today announced its participation in the Queensland World TB Day event at the Translational Research Institute in Brisbane. As sole sponsor, QIAGEN continued its multi-year commitment to Queensland Health’s Tuberculosis (TB) Program, supporting TB prevention and screening efforts statewide. In recognition of World Tuberculosis Day on March 24, the Queensland World TB Day event brings together healthcare professionals and public health stakeholders. The workshop provides an opportunity to review the current TB situation, share updates on progress

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here . QIAGEN will provide printed copies of the 2025 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2025 Annual Report please use our contact form or send an email to [email protected] . About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the

New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with tuberculin skin testing in people living with HIV CPD-accredited online QuantiFERON World TB Day program on March 24 convenes global experts to advance TB detection, prevention and high-impact scientific exchange QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-risk populations. The announcement is being made in time for World TB Day to underscore the continued importance of improving TB detection and prevention globally. The global QuantiFERON World TB Day event will take place online on March 24, 2026, with two identical sessions to enable participation across

FDA clears Gastrointestinal (GI) Panels for use on the fully automated QIAstat-Dx Rise platform, marking the ninth U.S. QIAstat-Dx panel clearance in last 24 months Laboratories can now run respiratory and gastrointestinal panels, including comprehensive and Mini panels, on one scalable automated system QIAstat-Dx Rise delivers higher-throughput automation for up to 160 tests per day with minimal hands-on time while supporting urgent sample prioritization QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx ® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndromic testing system. With this milestone, laboratories can run both QIAstat-Dx Respiratory and QIAstat-Dx GI panels on QIAstat-Dx Rise, the high-throughput version of the QIAstat-Dx system. Both versions support comprehensive syndromic testing with panels designed to detect multiple pathogens associated with

New chemistry reduces barriers to scaling single-cell studies across research settings Launch planned for March 2026, available across Evercode Whole Transcriptome product line Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to design large studies while maintaining sample resolution. The upgraded chemistry increases gene detection per cell while requiring fewer sequencing reads, helping reduce overall sequencing costs. A new magnetic bead-based workflow replaces centrifugation steps and increases cell recovery by up to 75%, allowing researchers to